AzurRx BioPharma Stock Price

-0.17 (-4.43%)
Upgrade to Real-Time
Regular Market


52 Week Range


Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
Canadian Level 1 + USA
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
AzurRx BioPharma Inc AZRX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.17 -4.43% 3.67 14:23:48
Open Price Low Price High Price Close Price Prev Close
3.84 3.57 3.845 3.84
Bid Price Ask Price Spread News
3.68 3.71 0.03 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
3,252 768,713 $ 3.68 $ 2,831,816 - 0.52005 - 6.00
Last Trade Time Type Quantity Stock Price Currency
14:24:27 20 $ 3.68 USD


Draw Mode:

AzurRx BioPharma Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 34.45M 9.34M 9.26M $ - $ - -11.45 -0.30
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 200.00k 1.50%

more financials information »

AzurRx BioPharma News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical AZRX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.64036.000.542.585,598,7543.03473.17%
1 Month0.586.000.541.533,160,1653.09532.76%
3 Months0.826.000.520050.86553924,439,8242.85347.56%
6 Months1.506.000.520050.93152593,400,9572.17144.67%
1 Year0.816.000.520051.293,938,2152.86353.09%
3 Years2.616.000.3708681.271,476,2711.0640.61%
5 Years5.066.000.3708681.31917,617-1.39-27.47%

AzurRx BioPharma Description

AzurRx BioPharma Inc is a development stage biopharmaceutical company. The company is focused on the development of recombinant proteins for the treatment of gastrointestinal diseases and microbiome-related conditions. Its lead product candidate is MS1819, a yeast-derived recombinant lipase for exocrine pancreatic insufficiency (EPI) associated with cystic fibrosis (CF) and chronic pancreatitis (CP).

Your Recent History
AzurRx Bio..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.